Thrombin Market

Thrombin Market (Product: Bovine Thrombin, Human Thrombin, and Recombinant Thrombin; and Dosage Form: Powder Form, Solution Form, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Thrombin Market Outlook 2031

  • The global industry was valued at US$ 652.2 Mn in 2022
  • It is estimated to grow at a CAGR of 6.1% from 2023 to 2031 and reach US$ 1.1 Bn by the end of 2031

Analyst Viewpoint

Increase in number of road accidents due to growth in traffic and availability of medical facilities in emergencies is fostering the thrombin market growth. Thrombin helps control heavy blood loss during surgeries, thereby allowing surgeons to operate patients efficiently. Furthermore, increase in prevalence of inherited blood coagulation diseases is driving the demand for thrombin. Healthcare professionals prefer thrombin due to its procoagulant properties.

Rise in R&D activities in the pharmaceutical sector for drug development to treat inherited blood-related disorders and government initiatives to improve availability of medical facilities in developing regions are generating lucrative thrombin market opportunities. Leading players in the market are focusing on new drug development strategies to meet the surge in demand for thrombin from healthcare organizations.

Thrombin Market

Market Introduction

Thrombin is a serine protease blood plasma protein used to convert fibrinogen to soluble fibrin. Thrombin helps catalyze the blood coagulation process with its unique molecule functions; as a procoagulant, it activates platelets through its receptor on platelets. Thrombin is used to control excessive bleeding and clotting during medical surgeries. Additionally, thrombin is used in diagnostic centers & clinics in several applications, such as coagulation assays, defibrination of blood or plasma, and clotting factor tests.

Bovine thrombin, human thrombin, and recombinant thrombin are major types of thrombin utilized in medical surgeries and diagnostic centers. Bovine thrombin is an enzyme that converts fibrinogen to fibrin. It is used in the defibrination of plasma to produce serum matrixes to be used as standards and controls. Human thrombin is a sterile solution containing highly purified human thrombin to activate clotting. Human thrombin is indicated as an aid to hemostasis during minor bleeding from small venules and capillaries.

Increase in Number of Road Accidents Augmenting Thrombin Market Size

Thrombin is employed to control excessive blood flow during complex surgeries to treat severe injuries and trauma. Increase in number of road accidents and injuries is fueling market statistics. Thrombin is utilized in safer hemostatic conditions and postoperative complications to ensure faster recovery from traumas. Road accidents are increasing due to the negligence on roads and non-adherence to road safety rules. According to the thrombin market forecast, growth in hospitalizations due to road accidents is projected to fuel market development.

According to the World Health Organization, every year around 1.3 billion people die due to road traffic crashes. Approximately 20 to 50 million people suffer from non-fatal injuries, with many incurring a disability. Increase in investments by governments for quick hospitalization post-accidents is increasing the number of surgeries, thereby driving the use of thrombin.

Growth in R&D Activities in Pharmaceutical Sector Driving Market Expansion

Companies in the drug development industry are investing in research and development activities to provide appropriate treatments for blood-related diseases or disorders. Thrombin is a crucial element used to treat several blood coagulation disorders, such as Von Willebrand disease, hypercoagulable states, hemophilia, and deep venous thrombosis. Increase in R&D activities by companies operating in the pharmaceutical sector to launch new drugs for these disorders is boosting the thrombin market revenue.

Vitro study, protein-structure analysis, coagulation research, and medical & biochemical research are ongoing market trends in bovine-derived thrombin products. Rise in demand for bovine thrombin in the diagnostics sector for clotting factor tests, coagulation assays, and defibrination of blood or plasma, is fueling market dynamics.

Regional Outlook

As per the thrombin market analysis, North America accounted for largest share in 2022. Road safety concerns due to growth in traffic across the region is likely to increase the number of accidents that occur due to lack of traffic management. Well-established healthcare infrastructure in the region ensures immediate treatment and easy access to required medical facilities in case of emergencies. Thus, growth in number of road accidents and availability of treatment options are major factors bolstering the thrombin industry share. As per data published by Forbes, a total of 35,766 fatal car accidents occurred on roadways in the United States in 2020. Another 1,593,390 accidents resulted in injuries leading to severe disabilities among people.

Furthermore, increase in prevalence of inherited blood disorders, such as hemophilia, is propelling the market value. According to the World Federation of Hemophilia, approximately 11,790 patients with Hemophilia A and 3,026 patients with Hemophilia B were diagnosed in the United States in 2020.

Analysis of Key Players in Thrombin Industry

Partnerships, new product launches, innovation in production lines, and research & development activities are major strategies adopted by leading market players. Capabilities to invest in innovative product development methodologies allow companies to deliver high-quality and efficient treatment to patients. Pharmaceutical companies invest substantially in conducting clinical trials to ensure efficiency of drugs and evaluate correct dosage according to the severity of disease and the patient’s condition.

Some of the leading companies in the industry are Johnson & Johnson, Pfizer, Inc., Mallinckrodt Pharmaceuticals, Shanghai RAAS Blood Products Co., Ltd., Japan Blood Products Organization, Mochida Pharmaceutical Co., Ltd., BIOFAC A/S, Biomed-Lublin S.A., and Hualan Biological Engineering, Inc.

These companies are profiled in the thrombin market report based on parameters such as company overview, financial overview, business segments, product portfolio, business strategies, and key developments.

Key Developments

  • In April 2022, Bayer AG, a multinational pharmaceutical and biotechnology company, announced that its new thrombosis prevention drug, Asundexian, demonstrated positive results in a clinical study designed to assess its safety and determine the optimal dosage.
  • In February 2022, CTI BioPharma, a leading company focusing on therapies for blood-related cancers, received approval from the United States Food and Drug Administration (FDA) for VONJO to treat adults with intermediate or high-risk primary or secondary myelofibrosis, including post-polycythemia Vera or post-essential thrombocythemia.

Thrombin Market Overview

Attribute Detail
Market Size in 2022 US$ 652.2 Mn
Market Forecast (Value) in 2031 US$ 1.1 Bn
Growth Rate (CAGR) 6.1%
Forecast Period 2023-2031
Historical Data Available for 2017-2021
Quantitative Tons US$ Bn/Mn for Value
Market Analysis It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces Analysis, value chain analysis, and key trend analysis.
Competition Landscape
  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy and recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • Product
    • Bovine Thrombin
    • Human Thrombin
    • Recombinant Thrombin
  • Dosage Form
    • Powder Form
    • Solution Form
    • Others
  • End-user
    • Hospitals
    • Diagnostic Centers & Clinics
    • Academic & Research Institutes
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Japan
  • China
  • India
  • Australia & New Zealand
  • Brazil
  • Mexico
  • South Africa
  • GCC countries
Companies Profiled
  • Johnson & Johnson
  • Pfizer, Inc.
  • Mallinckrodt Pharmaceuticals
  • Shanghai RAAS Blood Products Co., Ltd.
  • Japan Blood Products Organization
  • Mochida Pharmaceutical Co., Ltd.
  • BIOFAC A/S
  • Biomed-Lublin S.A.
  • Hualan Biological Engineering, Inc.
Customization Scope Available upon request
Pricing Available upon request

Frequently Asked Questions

How big was the global thrombin market in 2022?

It was valued at US$ 652.2 Mn in 2022

How is the thrombin industry expected to grow during the forecast period?

It is projected to register a CAGR of 6.1% from 2023 to 2031

What are the key factors driving the demand for thrombin?

Increase in number of road accidents and growth in R&D activities in the pharmaceutical sector

Which was the most lucrative region for thrombin in 2022?

North America was the most lucrative region in 2022

Who are the prominent thrombin manufacturers?

Johnson & Johnson, Pfizer, Inc., Mallinckrodt Pharmaceuticals, Shanghai RAAS Blood Products Co., Ltd., Japan Blood Products Organization, Mochida Pharmaceutical Co., Ltd., BIOFAC A/S, Biomed-Lublin S.A., and Hualan Biological Engineering, Inc.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Thrombin Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Product Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Thrombin Market Analysis and Forecasts, 2023–2031

    5. Key Insights

        5.1. Current Trends in Thrombin

        5.2. Technological advancements in Thrombin

        5.3. COVID-19 Impact Analysis

    6. Global Thrombin Market Analysis and Forecasts, by Product

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Product, 2023–2031

            6.3.1. Bovine Thrombin

            6.3.2. Human Thrombin

            6.3.3. Recombinant Thrombin

        6.4. Market Attractiveness Analysis, by Product

    7. Global Thrombin Market Analysis and Forecasts, by Dosage Form

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast, by Dosage Form, 2023–2031

            7.3.1. Powder Form

            7.3.2. Solution Form

            7.3.3. Others

        7.4. Market Attractiveness Analysis, by Dosage Form

    8. Global Thrombin Market Analysis and Forecasts, by End-user

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast, by End-user, 2023–2031

            8.3.1. Hospitals

            8.3.2. Diagnostic Centers & Clinics

            8.3.3. Academic & Research Institutes

        8.4. Market Attractiveness Analysis, by End-user

    9. Global Thrombin Market Analysis and Forecasts, by Region

        9.1. Key Findings

        9.2. Market Value Forecast, by Region

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. Market Attractiveness Analysis, by Region

    10. North America Thrombin Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Product, 2023–2031

            10.2.1. Bovine Thrombin

            10.2.2. Human Thrombin

            10.2.3. Recombinant Thrombin

        10.3. Market Value Forecast, by Dosage Form, 2023–2031

            10.3.1. Powder Form

            10.3.2. Solution Form

            10.3.3. Others

        10.4. Market Value Forecast, by End-user, 2023–2031

            10.4.1. Hospitals

            10.4.2. Diagnostic Centers & Clinics

            10.4.3. Academic & Research Institutes

        10.5. Market Value Forecast, by Country, 2023–2031

            10.5.1. U.S.

            10.5.2. Canada

        10.6. Market Attractiveness Analysis

            10.6.1. By Product

            10.6.2. By Dosage Form

            10.6.3. By End-user

            10.6.4. By Country

    11. Europe Thrombin Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Product, 2023–2031

            11.2.1. Bovine Thrombin

            11.2.2. Human Thrombin

            11.2.3. Recombinant Thrombin

        11.3. Market Value Forecast, by Dosage Form, 2023–2031

            11.3.1. Powder Form

            11.3.2. Solution Form

            11.3.3. Others

        11.4. Market Value Forecast, by End-user, 2023–2031

            11.4.1. Hospitals

            11.4.2. Diagnostic Centers & Clinics

            11.4.3. Academic & Research Institutes

        11.5. Market Value Forecast, by Country/Sub-region, 2023–2031

            11.5.1. Germany

            11.5.2. U.K.

            11.5.3. France

            11.5.4. Italy

            11.5.5. Spain

            11.5.6. Rest of Europe

        11.6. Market Attractiveness Analysis

            11.6.1. By Product

            11.6.2. By Dosage Form

            11.6.3. By End-user

            11.6.4. By Country/Sub-region

    12. Asia Pacific Thrombin Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Product, 2023–2031

            12.2.1. Bovine Thrombin

            12.2.2. Human Thrombin

            12.2.3. Recombinant Thrombin

        12.3. Market Value Forecast, by Dosage Form, 2023–2031

            12.3.1. Powder Form

            12.3.2. Solution Form

            12.3.3. Others

        12.4. Market Value Forecast, by End-user, 2023–2031

            12.4.1. Hospitals

            12.4.2. Diagnostic Centers & Clinics

            12.4.3. Academic & Research Institutes

        12.5. 12.5. Market Value Forecast, by Country/Sub-region, 2023–2031

            12.5.1. China

            12.5.2. India

            12.5.3. Japan

            12.5.4. Australia & New Zealand

            12.5.5. Rest of Asia Pacific

        12.6. Market Attractiveness Analysis

            12.6.1. By Product

            12.6.2. By Dosage Form

            12.6.3. By End-user

            12.6.4. By Country/Sub-region

    13. Latin America Thrombin Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Product, 2023–2031

            13.2.1. Bovine Thrombin

            13.2.2. Human Thrombin

            13.2.3. Recombinant Thrombin

        13.3. Market Value Forecast, by Dosage Form, 2023–2031

            13.3.1. Powder Form

            13.3.2. Solution Form

            13.3.3. Others

        13.4. Market Value Forecast, by End-user, 2023–2031

            13.4.1. Hospitals

            13.4.2. Diagnostic Centers & Clinics

            13.4.3. Academic & Research Institutes

        13.5. Market Value Forecast, by Country/Sub-region, 2023–2031

            13.5.1. Brazil

            13.5.2. Mexico

            13.5.3. Rest of Latin America

        13.6. Market Attractiveness Analysis

            13.6.1. By Product

            13.6.2. By Dosage Form

            13.6.3. By End-user

            13.6.4. By Country/Sub-region

    14. Middle East & Africa Thrombin Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Product, 2023–2031

            14.2.1. Bovine Thrombin

            14.2.2. Human Thrombin

            14.2.3. Recombinant Thrombin

        14.3. Market Value Forecast, by Dosage Form, 2023–2031

            14.3.1. Powder Form

            14.3.2. Solution Form

            14.3.3. Others

        14.4. Market Value Forecast, by End-user, 2023–2031

            14.4.1. Hospitals

            14.4.2. Diagnostic Centers & Clinics

            14.4.3. Academic & Research Institutes

        14.5. Market Value Forecast, by Country/Sub-region, 2023–2031

            14.5.1. GCC Countries

            14.5.2. South Africa

            14.5.3. Rest of Middle East & Africa

        14.6. Market Attractiveness Analysis

            14.6.1. By Product

            14.6.2. By Dosage Form

            14.6.3. By End-user

            14.6.4. By Country/Sub-region

    15. Competition Landscape

        15.1. Market Player – Competition Matrix (By Tier and Size of companies)

        15.2. Market Share Analysis, by Company (2022)

        15.3. Company Profiles

            15.3.1. Johnson & Johnson

                15.3.1.1. Company Overview

                15.3.1.2. Financial Overview

                15.3.1.3. Product Portfolio

                15.3.1.4. Strategic Overview

                15.3.1.5. SWOT Analysis

            15.3.2. Pfizer, Inc.

                15.3.2.1. Company Overview

                15.3.2.2. Financial Overview

                15.3.2.3. Product Portfolio

                15.3.2.4. Strategic Overview

                15.3.2.5. SWOT Analysis

            15.3.3. Mallinckrodt Pharmaceuticals

                15.3.3.1. Company Overview

                15.3.3.2. Financial Overview

                15.3.3.3. Product Portfolio

                15.3.3.4. Strategic Overview

                15.3.3.5. SWOT Analysis

            15.3.4. Shanghai RAAS Blood Products Co., Ltd.

                15.3.4.1. Company Overview

                15.3.4.2. Financial Overview

                15.3.4.3. Product Portfolio

                15.3.4.4. Strategic Overview

                15.3.4.5. SWOT Analysis

            15.3.5. Japan Blood Products Organization

                15.3.5.1. Company Overview

                15.3.5.2. Financial Overview

                15.3.5.3. Product Portfolio

                15.3.5.4. Strategic Overview

                15.3.5.5. SWOT Analysis

            15.3.6. Mochida Pharmaceutical Co., Ltd.

                15.3.6.1. Company Overview

                15.3.6.2. Financial Overview

                15.3.6.3. Product Portfolio

                15.3.6.4. Strategic Overview

                15.3.6.5. SWOT Analysis

            15.3.7. BIOFAC A/S

                15.3.7.1. Company Overview

                15.3.7.2. Financial Overview

                15.3.7.3. Product Portfolio

                15.3.7.4. Strategic Overview

                15.3.7.5. SWOT Analysis

            15.3.8. Biomed-Lublin S.A.

                15.3.8.1. Company Overview

                15.3.8.2. Financial Overview

                15.3.8.3. Product Portfolio

                15.3.8.4. Strategic Overview

                15.3.8.5. SWOT Analysis

            15.3.9. Hualan Biological Engineering, Inc.

                15.3.9.1. Company Overview

                15.3.9.2. Financial Overview

                15.3.9.3. Product Portfolio

                15.3.9.4. Strategic Overview

                15.3.9.5. SWOT Analysis

    List of Tables

    Table 01: Global Thrombin Market Value (US$ Mn) Forecast, by Product, 2023–2031

    Table 02: Global Thrombin Market Value (US$ Mn) Forecast, by Dosage Form, 2023–2031

    Table 03: Global Thrombin Market Value (US$ Mn) Forecast, by End-user, 2023–2031

    Table 04: Global Thrombin Market Value (US$ Mn) Forecast, by Region, 2023–2031

    Table 05: North America Thrombin Market Value (US$ Mn) Forecast, by Product, 2023–2031

    Table 06: North America Thrombin Market Value (US$ Mn) Forecast, by Dosage Form, 2023–2031

    Table 07: North America Thrombin Market Value (US$ Mn) Forecast, by End-user, 2023–2031

    Table 08: North America Thrombin Market Value (US$ Mn) Forecast, by Country, 2023–2031

    Table 09: Europe Thrombin Market Value (US$ Mn) Forecast, by Product, 2023–2031

    Table 10: Europe Thrombin Market Value (US$ Mn) Forecast, by Dosage Form, 2023–2031

    Table 11: Europe Thrombin Market Value (US$ Mn) Forecast, by End-user, 2023–2031

    Table 12: Europe Thrombin Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2031

    Table 13: Asia Pacific Thrombin Market Value (US$ Mn) Forecast, by Product, 2023–2031

    Table 14: Asia Pacific Thrombin Market Value (US$ Mn) Forecast, by Dosage Form, 2023–2031

    Table 15: Asia Pacific Thrombin Market Value (US$ Mn) Forecast, by End-user, 2023–2031

    Table 16: Asia Pacific Thrombin Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2031

    Table 17: Latin America Thrombin Market Value (US$ Mn) Forecast, by Product, 2023–2031

    Table 18: Latin America Thrombin Market Value (US$ Mn) Forecast, by Dosage Form, 2023–2031

    Table 19: Latin America Thrombin Market Value (US$ Mn) Forecast, by End-user, 2023–2031

    Table 20: Latin America Thrombin Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2031

    Table 21: Middle East & Africa Thrombin Market Value (US$ Mn) Forecast, by Product, 2023–2031

    Table 22: Middle East & Africa Thrombin Market Value (US$ Mn) Forecast, by Dosage Form, 2023–2031

    Table 23: Middle East & Africa Thrombin Market Value (US$ Mn) Forecast, by End-user, 2023–2031

    Table 24: Middle East & Africa Thrombin Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2031

    List of Figures

    Figure 01: Global Thrombin Market Value (US$ Mn) Forecast, 2023–2031

    Figure 02: Global Thrombin Market Value Share Analysis, by Product, 2022 and 2031

    Figure 03: Global Thrombin Market Attractiveness Analysis, by Product, 2023–2031

    Figure 04: Global Thrombin Market Value Share Analysis, by Dosage Form 2022 and 2031

    Figure 05: Global Thrombin Market Attractiveness Analysis, by Dosage Form, 2023–2031

    Figure 06: Global Thrombin Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 07: Global Thrombin Market Attractiveness Analysis, by End-user, 2023–2031

    Figure 08: Global Thrombin Market Value Share Analysis, by Region, 2022 and 2031

    Figure 09: Global Thrombin Market Attractiveness Analysis, by Region, 2023–2031

    Figure 10: North America Thrombin Market Value (US$ Mn) Forecast, 2023–2031

    Figure 11: North America Thrombin Market Value Share Analysis, by Product, 2022 and 2031

    Figure 12: North America Thrombin Market Attractiveness Analysis, by Product, 2023–2031

    Figure 13: North America Thrombin Market Value Share Analysis, by Dosage Form, 2022 and 2031

    Figure 14: North America Thrombin Market Attractiveness Analysis, by Dosage Form, 2023–2031

    Figure 15: North America Thrombin Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 16: North America Thrombin Market Attractiveness Analysis, by End-user, 2023–2031

    Figure 17: North America Thrombin Market Value Share Analysis, by Country, 2022 and 2031

    Figure 18: North America Thrombin Market Attractiveness Analysis, by Country, 2023–2031

    Figure 19: Europe Thrombin Market Value (US$ Mn) Forecast, 2023–2031

    Figure 20: Europe Thrombin Market Value Share Analysis, by Product, 2022 and 2031

    Figure 21: Europe Thrombin Market Attractiveness Analysis, by Product, 2023–2031

    Figure 22: Europe Thrombin Market Value Share Analysis, by Dosage Form, 2022 and 2031

    Figure 23: Europe Thrombin Market Attractiveness Analysis, by Dosage Form, 2023–2031

    Figure 24: Europe Thrombin Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 25: Europe Thrombin Market Attractiveness Analysis, by End-user, 2023–2031

    Figure 26: Europe Thrombin Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 27: Europe Thrombin Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 28: Asia Pacific Thrombin Market Value (US$ Mn) Forecast, 2023–2031

    Figure 29: Asia Pacific Thrombin Market Value Share Analysis, by Product, 2022 and 2031

    Figure 30: Asia Pacific Thrombin Market Attractiveness Analysis, by Product, 2023–2031

    Figure 31: Asia Pacific Thrombin Market Value Share Analysis, by Dosage Form 2022 and 2031

    Figure 32: Asia Pacific Thrombin Market Attractiveness Analysis, by Dosage Form, 2023–2031

    Figure 33: Asia Pacific Thrombin Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 34: Asia Pacific Thrombin Market Attractiveness Analysis, by End-user, 2023–2031

    Figure 35: Asia Pacific Thrombin Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 36: Asia Pacific Thrombin Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 37: Latin America Thrombin Market Value (US$ Mn) Forecast, 2023–2031

    Figure 38: Latin America Thrombin Market Value Share Analysis, by Product, 2022 and 2031

    Figure 39: Latin America Thrombin Market Attractiveness Analysis, by Product, 2023–2031

    Figure 40: Latin America Thrombin Market Value Share Analysis, by Dosage Form, 2022 and 2031

    Figure 41: Latin America Thrombin Market Attractiveness Analysis, by Dosage Form, 2023–2031

    Figure 42: Latin America Thrombin Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 43: Latin America Thrombin Market Attractiveness Analysis, by End-user, 2023–2031

    Figure 44: Latin America Thrombin Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 45: Latin America Thrombin Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 46: Middle East & Africa Thrombin Market Value (US$ Mn) Forecast, 2023–2031

    Figure 47: Middle East & Africa Thrombin Market Value Share Analysis, by Product, 2022 and 2031

    Figure 48: Middle East & Africa Thrombin Market Attractiveness Analysis, by Product, 2023–2031

    Figure 49: Middle East & Africa Thrombin Market Value Share Analysis, by Dosage Form, 2022 and 2031

    Figure 50: Middle East & Africa Thrombin Market Attractiveness Analysis, by Dosage Form, 2023–2031

    Figure 51: Middle East & Africa Thrombin Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 52: Middle East & Africa Thrombin Market Attractiveness Analysis, by End-user, 2023–2031

    Figure 53: Middle East & Africa Thrombin Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 54: Middle East & Africa Thrombin Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 55: Global Thrombin Market Share Analysis, by Company, 2022

Copyright © Transparency Market Research, Inc. All Rights reserved